TNGX — Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 155
- Website: https://www.tangotx.com
Latest SEC filings for TNGX
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G — 2026-08-14
- SCHEDULE 13G/A — 2026-08-12
- 8-K — 2026-08-11
- 8-K — 2026-08-11
- 10-Q — 2026-08-11
- 424B5 — 2026-08-11
- 424B5 — 2026-08-11
- 8-K/A — 2026-08-07
Latest TNGX news
- — Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 (GlobeNewswire Inc.)
- — Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
Educational tool only — not investment advice.